Open AccessPrecision targeting tumor cells using cancer-specific InDel mutations with CRISPR-Cas9
Author(s) -
Taejoon Kwon,
Jae Sun,
So-Young Lee,
InJoon Baek,
Keon Woo Khim,
Eun A Lee,
Eun Kyung Song,
Daniyar Otarbayev,
Woojae Jung,
Yong Hwan Park,
Minwoo Wie,
Juyoung Bae,
Himchan Cheng,
Jun-Hong Park,
Namwoo Kim,
Yuri Seo,
Seongmin Yun,
Ha Eun Kim,
Hyo Eun Moon,
Sun Ha Paek,
Tae Joo Park,
Young Un Park,
Hwanseok Rhee,
Jang Hyun Choi,
Seung Woo Cho,
Kyungjae Myung
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2103532119
Subject(s) - indel , crispr , indel mutation , genetics , biology , mutation , computational biology , cancer , cancer research , gene , genotype , single nucleotide polymorphism
Significance The targeted killing of cancer cells without affecting surrounding normal cells is the most desirable approach for cancer therapy; however, it cannot be easily achieved, owing to the shared properties of normal and cancer cells. Using CRISPR-Cas9 targeting multiple cancer-specific mutations, we developed an innovative approach called cancer-specific insertions and deletions attacker that can induce targeted cancer cell death by simultaneous and multiple DNA double-strand breaks. As demonstrated in cell lines, cancer patient–driven cells and xenografts, the concept proposed in this study may become a potential approach for personalized cancer treatments.